The large number of biologic drug patents in the United States has contributed to delays in biosimilar availability.
References
Biosimilars in the United States: Competition, Savings, and Sustainability (IQVIA, 2020); https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/iqvia-institute-biosimilars-in-the-united-states.pdf
Ferris, L. K., Gellad, W. F. & Hernandez, I. JAMA Dermatol. 156, 1136–1138 (2020).
Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals (FDA, accessed 6 August 2021); https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process
Sarpatwari, A., Barenie, R. & Curfman, G. Clin. Pharmacol. Ther. 105, 92–100 (2019).
FDA approvals. Big Molecule Watch (accessed 29 December 2021); https://www.bigmoleculewatch.com/fda-approved-ablas/
Biosimilar approval status. Biosimilars Review and Report (accessed 23 December 2021); https://biosimilarsrr.com/us-biosimilar-filings/
Medicines (EMA, accessed 23 December 2021); https://www.ema.europa.eu/en/medicines
Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices (IMAK, 2018); https://www.i-mak.org/wp-content/uploads/2018/08/I-MAK-Overpatented-Overpriced-Report.pdf
Druedahl, L. C. et al. Nat. Biotechnol. 38, 1253–1256 (2020).
Van de Wiele, V. L., Kesselheim, A. S. & Sarpatwari, A. Health Aff. 40, 1198–1205 (2021).
Price, W. N. & Rai, A. K. Iowa Law Rev. 101, 1023–1063 (2016).
Drug Pricing and Pharmaceutical Patenting Practices (Congressional Research Service, 2020); https://fas.org/sgp/crs/misc/R46221.pdf
BPCIA Litigations (Big Molecule Watch, accessed 13 May 2021); https://www.bigmoleculewatch.com/bpcia-patent-litigations/
Patent Term Calculator (USPTO, accessed 6 August 2021); https://www.uspto.gov/patents/laws/patent-term-calculator
Beall, R. F., Darrow, J. J. & Kesselheim, A. S. Value Health 21, 1382–1389 (2018).
Vilcek, J. Nat. Immunol. 10, 555–557 (2009).
Pelechas, E., Voulgari, P. V. & Drosos, A. A. Expert Opin. Drug Discov. 16, 227–234 (2021).
Hemphill, C. S. & Sampat, B. Science 339, 1386–1387 (2013).
Rai, A. K. & Price, W. N. II Nat. Biotechnol. 39, 20–22 (2021).
Bergman, M., Patel, P., Chen, N., Jing, Y. & Saffore, C. D. Rheumatol. Ther. 8, 109–118 (2021).
Chung, A. Europe issues better patents than US – Europe patent boss. Reuters (15 September 2016).
Picard, P. M. & van Pottelsberghe de la Portterie, B. J. Public Econ. 104, 14–25 (2013).
Moorkens, E., Vulto, A. G. & Huys, I. MAbs 12, 1743517 (2020).
Feldman, R. Drugs, Money, and Secret Handshakes (Cambridge Univ. Press, 2019).
Bloomfield, D. & Kesselheim, A.S. Biden can lower drug prices without Congress doing anything. Washington Post (5 January 2021).
Frakes, M.D. & Wasserman, M.F. Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination (NBER, 2020); https://www.nber.org/papers/w27579
Acknowledgements
This work was supported by Arnold Ventures.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Van de Wiele, V.L., Beall, R.F., Kesselheim, A.S. et al. The characteristics of patents impacting availability of biosimilars. Nat Biotechnol 40, 22–25 (2022). https://doi.org/10.1038/s41587-021-01170-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-01170-5
- Springer Nature America, Inc.
This article is cited by
-
Biologic patent challenges under the America Invents Act
Nature Biotechnology (2024)
-
The prevalence of drug patent term extensions in the United States, 2000–2018
Nature Biotechnology (2023)